BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee L, Ito T, Jensen RT. Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies. Expert Rev Anticancer Ther. 2019;19:1029-1050. [PMID: 31738624 DOI: 10.1080/14737140.2019.1693893] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Soczomski P, Jurecka-Lubieniecka B, Krzywon A, Cortez AJ, Zgliczynski S, Rogozik N, Oczko-Wojciechowska M, Pawlaczek A, Bednarczuk T, Jarzab B. A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype-Phenotype Correlations. Front Endocrinol (Lausanne) 2021;12:681013. [PMID: 34122352 DOI: 10.3389/fendo.2021.681013] [Reference Citation Analysis]
2 Xie S, Li L, Wang X, Li L. Development and validation of a nomogram for predicting the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms. Medicine (Baltimore) 2021;100:e24223. [PMID: 33466202 DOI: 10.1097/MD.0000000000024223] [Reference Citation Analysis]
3 Cukier M, Vergara R, Mendez-Rios JD, Castillo O, Barrera I, Tello E, El Achtar O, Loo Y, Tapia H, Perez G, Peña M. Neuroendocrine tumors in Panama: A nationwide database analysis. Mol Clin Oncol 2021;15:157. [PMID: 34178328 DOI: 10.3892/mco.2021.2319] [Reference Citation Analysis]
4 Chen J, Yang Y, Liu Y, Kan H. Prognosis analysis of patients with pancreatic neuroendocrine tumors after surgical resection and the application of enucleation. World J Surg Oncol 2021;19:11. [PMID: 33436017 DOI: 10.1186/s12957-020-02115-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Kim J, Hwang HK, Lee WJ, Kang CM. Minimally invasive vs open pancreatectomy for nonfunctioning pancreatic neuroendocrine tumors. World J Gastrointest Oncol 2020; 12(10): 1133-1145 [PMID: 33133382 DOI: 10.4251/wjgo.v12.i10.1133] [Reference Citation Analysis]
6 Bian Y, Jiang H, Zheng J, Shao C, Lu J. Basic pancreatic lesions: Radiologic-pathologic correlation. Journal of Translational Internal Medicine 2022;10:18-27. [DOI: 10.2478/jtim-2022-0003] [Reference Citation Analysis]
7 Ito T, Jensen RT. Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes. Expert Opin Pharmacother 2021;22:685-93. [PMID: 33131345 DOI: 10.1080/14656566.2020.1845651] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Ma ST, Wang DY, Liu YB, Tan HJ, Ge YY, Chi Y, Zhang BL. Prognostic factors of primary neuroendocrine breast cancer: A population-based study. Cancer Med 2022. [PMID: 35499193 DOI: 10.1002/cam4.4557] [Reference Citation Analysis]
9 Brandi ML, Agarwal SK, Perrier ND, Lines KE, Valk GD, Thakker RV. Multiple Endocrine Neoplasia Type 1: Latest Insights. Endocr Rev 2021;42:133-70. [PMID: 33249439 DOI: 10.1210/endrev/bnaa031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 He R, Zhang W, Chen S, Liu Y, Yang W, Li J. Transcriptional Profiling Reveals the Regulatory Role of DNER in Promoting Pancreatic Neuroendocrine Neoplasms. Front Genet 2020;11:587402. [PMID: 33329729 DOI: 10.3389/fgene.2020.587402] [Reference Citation Analysis]
11 Huang J, Xie X, Wu H, Zhang X, Zheng Y, Xie X, Wang Y, Xu M. Development and validation of a combined nomogram model based on deep learning contrast-enhanced ultrasound and clinical factors to predict preoperative aggressiveness in pancreatic neuroendocrine neoplasms. Eur Radiol 2022. [PMID: 35389050 DOI: 10.1007/s00330-022-08703-9] [Reference Citation Analysis]
12 Lu X, Yan S, Koral KA, Chen Z. Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors. Expert Rev Anticancer Ther 2021;21:917-26. [PMID: 34142932 DOI: 10.1080/14737140.2021.1944110] [Reference Citation Analysis]
13 Liao T, Su T, Huang L, Li B, Feng LH. Development and validation of a novel nomogram for predicting survival rate in pancreatic neuroendocrine neoplasms. Scand J Gastroenterol 2021;:1-6. [PMID: 34592854 DOI: 10.1080/00365521.2021.1984571] [Reference Citation Analysis]
14 Viúdez A, Crespo G, Gómez Dorronsoro ML, Arozarena I, Marín-Méndez JJ, Custodio A, Benavent M, Goñi S, García-Paredes B, Hernando J, Durantez M, Alonso V, Riesco MDC, López C, Jiménez-Fonseca P, San Vicente BL, González-Borja I, Sevilla I, Hernández-Garcia I, Carmona-Bayonas A, Capdevila J, Pérez-Sanz J, García-Carbonero R, Pérez-Ricarte L, Llanos M, Vera R, De Jesús Acosta A. Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus. Pancreatology 2021;21:215-23. [PMID: 33358592 DOI: 10.1016/j.pan.2020.12.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Chen BB. Artificial intelligence in pancreatic disease. Artif Intell Med Imaging 2020; 1(1): 19-30 [DOI: 10.35711/aimi.v1.i1.19] [Reference Citation Analysis]
16 Hou J, Yang Y, Chen N, Chen D, Hu S. Prognostic Value of Volume-Based Parameters Measured by SSTR PET/CT in Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021;8:771912. [PMID: 34901087 DOI: 10.3389/fmed.2021.771912] [Reference Citation Analysis]
17 Aysal A, Agalar C, Egeli T, Unek T, Oztop I, Obuz F, Sagol O. Reconsideration of Clinicopathologic Prognostic Factors in Pancreatic Neuroendocrine Tumors for Better Determination of Adverse Prognosis. Endocr Pathol 2021. [PMID: 34283399 DOI: 10.1007/s12022-021-09687-w] [Reference Citation Analysis]
18 Sadowski SM, Pieterman CRC, Perrier ND, Triponez F, Valk GD. Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature. Endocr Relat Cancer 2020;27:R145-61. [PMID: 32229700 DOI: 10.1530/ERC-19-0372] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
19 Hou J, Long T, Yang Y, Chen D, Hu S, Azhdarinia A. The Potential Prognostic Value of Dual-Imaging PET Parameters Based on 18F-FDG and 18F-OC for Neuroendocrine Neoplasms. Molecular Imaging 2022;2022:1-9. [DOI: 10.1155/2022/6511179] [Reference Citation Analysis]
20 Wang J, Liu J, He C, Sun T, Yan Y, Che G, Li X, Sun H, Ma H. Trends in Incidence and Survival of Patients with Pancreatic Neuroendocrine Neoplasm, 1987-2016. J Oncol 2021;2021:4302675. [PMID: 34976056 DOI: 10.1155/2021/4302675] [Reference Citation Analysis]
21 Shyr BS, Shyr BU, Chen SC, Shyr YM, Wang SE. Impact of tumor grade on pancreatic neuroendocrine tumors. Asian J Surg 2022:S1015-9584(22)00149-X. [PMID: 35246343 DOI: 10.1016/j.asjsur.2022.01.094] [Reference Citation Analysis]